Covid-19 Research

Retrospective Cohort Study

Rheumatoid Arthritis Disability and Absence Trends in the United States

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Retrospective Cohort Study
Subject Medicine Group
OCLC 9385833041
Richard A Brook*, Nathan L Kleinman and Ian A Beren
Issue: Volume2-Issue12
Pages: 1238-1245
Received: 2021-11-30
Accepted: 2021-12-27
Published: 2021-12-28

Abstract

Objectives: Employers increasingly focus on absence benefits and connections with employee health. United States absence benefits include Sick Leave (SL), Short- and Long-Term Disability (STD and LTD, respectively) for non-work-related injuries/illnesses, and Workers’ Compensation (WC) for work-related injuries/illnesses. This research explores all-cause absence (SL, STD, LTD, and WC) utilization and changes from baseline for eligible employees with rheumatoid arthritis to determine if the use a constant payment factor is appropriate for models.

Study Design: Retrospective multi-year database analysis.

Methods: The Workpartners database (1/1/2001-12/31/2019) was used to identify employees with rheumatoid arthritis with adjudicated medical claims. Annual prevalence, benefit utilization, mean days of leave, and median payments (as % of salary) were analyzed. Annual outcomes were calculated as a percent of baseline (2001).

Results: Rheumatoid arthritis prevalence averaged 0.5% between 2001 and 2019. At baseline, the percent of eligible employees using STD = 15.5%, LTD = 0.7%, WC = 1.7%, SL = 61.7%. Mean absence days were 48.5, 367.5, 43.8 for STD, LTD, WC, respectively and median payments were 70.5%, 22.2%, 65.7% of salary for STD, LTD, WC, respectively. From 2002-2019: 11.7%-16.9% of eligible employees filed STD claims for 82.1%-995.9% of baseline days and 80.4%-125.9% median payments; 0.6%-2.9% of eligible employees filed LTD claims for 66.6%-114.7% of baseline days and 63.2%-254.8% median payments; 0.3%-1.6% of eligible employees filed WC claims for 44.0%-472.8% of baseline days and 70.4%-271.5% median payments. Median payments were highest in 2012, 2019, 2003 for STD, LTD, WC, respectively and the most absence days were used in 2017 for SL and LTD, 2008 for STD, and 2005
WC.

Conclusion: Employees with rheumatoid arthritis used absence benefits at differing rates over time with varying leave-lengths and payments. Using a constant cost or salary replacement factor for absence costs over time and across benefits is not accurate.

FullText HTML FullText PDF DOI: 10.37871/jbres1378 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2021 Brook RA, et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Brook RA, Kleinman NL, Beren IA. Rheumatoid Arthritis Disability and Absence Trends in the United States. J Biomed Res Environ Sci. 2021 Dec 28; 2(12): 1238-1245. doi: 10.37871/jbres1378, Article ID: JBRES1378, Available at: https://www.jelsciences.com/articles/jbres1378.pdf

Subject area(s)

RheumatologyPain and ReliefOrthopedicsPhysiology

References

  1. Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003 Nov 12;290(18):2443-54. doi: 10.1001/jama.290.18.2443. PMID: 14612481.
  2. Murphy LB, Cisternas MG, Pasta DJ, Helmick CG, Yelin EH. Medical Expenditures and Earnings Losses Among US Adults With Arthritis in 2013. Arthritis Care Res (Hoboken). 2018 Jun;70(6):869-876. doi: 10.1002/acr.23425. Epub 2018 Apr 16. PMID: 28950426.
  3. Barbour KE, Helmick CG, Boring M, Brady TJ. Vital Signs: Prevalence of Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation - United States, 2013-2015. MMWR Morb Mortal Wkly Rep. 2017 Mar 10;66(9):246-253. doi: 10.15585/mmwr.mm6609e1. PMID: 28278145; PMCID: PMC5687192.
  4. Healthy People 2030 Arthritis Workgroup. Office of Disease Prevention and Health Promotion, Office of the Assistant Secretary for Health, Office of the Secretary, U.S. Department of Health and Human Services. 2021.
  5. Theis KA, Steinweg A, Helmick CG, Courtney-Long E, Bolen JA, Lee R. Which one? What kind? How many? Types, causes, and prevalence of disability among U.S. adults. Disabil Health J. 2019 Jul;12(3):411-421. doi: 10.1016/j.dhjo.2019.03.001. Epub 2019 Mar 28. PMID: 31000498.
  6. Hootman JM, Helmick CG, Barbour KE, Theis KA, Boring MA. Updated Projected Prevalence of Self-Reported Doctor-Diagnosed Arthritis and Arthritis-Attributable Activity Limitation Among US Adults, 2015-2040. Arthritis Rheumatol. 2016 Jul;68(7):1582-7. doi: 10.1002/art.39692. PMID: 27015600; PMCID: PMC6059375.
  7. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremers HM, Mayes MD, Merkel PA, Pillemer SR, Reveille JD, Stone JH; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008 Jan;58(1):15-25. doi: 10.1002/art.23177. PMID: 18163481.
  8. 8O’Dell JR. Rheumatoid arthritis. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, PA: Saunders Elsevier; 2007.
  9. Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet. 2001 Sep 15;358(9285):903-11. doi: 10.1016Gabriel SE, Crowson CS, O'Fallon WM. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis Rheum. 1999 Mar;42(3):415-20. doi: 10.1002/1529-0131(199904)42:3<415::AID-ANR4>3.0.CO;2-Z. PMID: 10088762.
  10. Treharne GJ, Hale ED, Lyons AC, Booth DA, Banks MJ, Erb N, Douglas KM, Mitton DL, Kitas GD. Cardiovascular disease and psychological morbidity among rheumatoid arthritis patients. Rheumatology (Oxford). 2005 Feb;44(2):241-6. doi: 10.1093/rheumatology/keh441. Epub 2004 Nov 2. PMID: 15522922.
  11. Gabriel SE. Cardiovascular morbidity and mortality in rheumatoid arthritis. Am J Med. 2008 Oct;121(10 Suppl 1):S9-14. doi: 10.1016/j.amjmed.2008.06.011. PMID: 18926169; PMCID: PMC2858687.
  12. Prior Y, Tennant A, Tyson S, Kjeken I, Hammond A. Measure of activity performance of the hand (MAP-Hand) questionnaire: linguistic validation, cultural adaptation and psychometric testing in people with rheumatoid arthritis in the UK. BMC Musculoskelet Disord. 2018 Jul 31;19(1):275. doi: 10.1186/s12891-018-2177-5. PMID: 30064399; PMCID: PMC6069818.
  13. Gunnarsson C, Chen J, Rizzo JA, Ladapo JA, Naim A, Lofland JH. The Employee Absenteeism Costs of Rheumatoid Arthritis: Evidence From US National Survey Data. J Occup Environ Med. 2015 Jun;57(6):635-42. doi: 10.1097/JOM.0000000000000461. PMID: 26053366.
  14. Arthritis By the Numbers: Book of Trusted Facts & Figures. Arthritis Foundation. 2019.
  15. Gabriel SE, Crowson CS, Kremers HM, et al. Survival in rheumatoid arthritis. Arthritis Rheum. 2003;48:54-58.
  16. https://bit.ly/3Jlcflt
  17. Mikuls TR. Rheumatoid arthritis incidence: what goes down must go up? Arthritis Rheum. 2010 Jun;62(6):1565-7. doi: 10.1002/art.27432. PMID: 20191577.
  18. Burton W, Morrison A, Maclean R, Ruderman E. Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med (Lond). 2006 Jan;56(1):18-27. doi: 10.1093/occmed/kqi171. Epub 2005 Nov 11. PMID: 16286432.
  19. Muchmore L, Lynch WD, Gardner HH, Williamson T, Burke T. Prevalence of arthritis and associated joint disorders in an employed population and the associated healthcare, sick leave, disability, and workers' compensation benefits cost and productivity loss of employers. J Occup Environ Med. 2003 Apr;45(4):369-78. doi: 10.1097/01.jom.0000063621.37065.26. PMID: 12708140.
  20. Wolfe F, Michaud K. Out-of-pocket expenses and their burden in patients with rheumatoid arthritis. Arthritis Rheum. 2009 Nov 15;61(11):1563-70. doi: 10.1002/art.24724. PMID: 19877107.
  21. Burton WN, Morrison A, Yuan Y, Li T, Marioni RE, Maclean R. Productivity cost model of the treatment of rheumatoid arthritis with abatacept. J Med Econ. 2008;11(1):3-21. doi: 10.3111/13696990701748837. PMID: 19450107.
  22. Neovius M, Simard JF, Klareskog L, Askling J; ARTIS Study Group. Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice. Ann Rheum Dis. 2011 Aug;70(8):1407-14. doi: 10.1136/ard.2010.144139. Epub 2011 Apr 25. PMID: 21518724.
  23. Neovius M, Simard JF, Askling J; ARTIS Study Group. How large are the productivity losses in contemporary patients with RA, and how soon in relation to diagnosis do they develop? Ann Rheum Dis. 2011 Jun;70(6):1010-5. doi: 10.1136/ard.2010.136812. Epub 2011 Mar 15. PMID: 21406455.
  24. Kleinman NL, Cifaldi MA, Smeeding JE, Shaw JW, Brook RA. Annual incremental health benefit costs and absenteeism among employees with and without rheumatoid arthritis. J Occup Environ Med. 2013 Mar;55(3):240-4. doi: 10.1097/JOM.0b013e318282d310. PMID: 23471034.
  25. Filipovic I, Walker D, Forster F, Curry AS. Quantifying the economic burden of productivity loss in rheumatoid arthritis. Rheumatology (Oxford). 2011 Jun;50(6):1083-90. doi: 10.1093/rheumatology/keq399. Epub 2011 Jan 18. PMID: 21245074.
  26. Ozminkowski RJ, Burton WN, Goetzel RZ, Maclean R, Wang S. The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. J Occup Environ Med. 2006 Feb;48(2):135-48. doi: 10.1097/01.jom.0000194161.12923.52. PMID: 16474262.
  27. Ma VY, Chan L, Carruthers KJ. Incidence, prevalence, costs, and impact on disability of common conditions requiring rehabilitation in the United States: stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, osteoarthritis, rheumatoid arthritis, limb loss, and back pain. Arch Phys Med Rehabil. 2014 May;95(5):986-995.e1. doi: 10.1016/j.apmr.2013.10.032. Epub 2014 Jan 21. PMID: 24462839; PMCID: PMC4180670.
  28. Harnett J, Gerber R, Gruben D, Koenig AS, Chen C. Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database. J Manag Care Spec Pharm. 2016 Dec;22(12):1457-1471. doi: 10.18553/jmcp.2016.22.12.1457. PMID: 27882833.
  29. Cavaliere CM, Chung KC. A cost-utility analysis of nonsurgical management, total wrist arthroplasty, and total wrist arthrodesis in rheumatoid arthritis. J Hand Surg Am. 2010 Mar;35(3):379-391.e2. doi: 10.1016/j.jhsa.2009.12.013. PMID: 20193858; PMCID: PMC2909683.
  30. Understanding Disability and Long Term Care Insurance Policies. 2021.
  31. Healthcare and Health Services SHRM Employee Benefits 2019. Society for Human Resource Management.
  32. Hunt HA. Is compensation for workplace injuries adequate? Employ Res. 2002;9:1-3.
  33. Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M. Societal cost of rheumatoid arthritis patients in the US. Curr Med Res Opin. 2010 Jan;26(1):77-90. doi: 10.1185/03007990903422307. PMID: 19908947.
  34. Brook RA, Kleinman NL, Patel S, Smeeding JE, Beren IA, Turpcu A. United States comparative costs and absenteeism of diabetic ophthalmic conditions. Postgrad Med. 2015 Jun;127(5):455-62. doi: 10.1080/00325481.2014.994468. Epub 2014 Dec 31. PMID: 25549691.
  35. Kleinman NL, Brook RA, Patel PA, et al. The impact of gout on work absence and productivity. Value Health. 2007 Jul-Aug;10(4):231-7. doi: 10.1111/j.1524-4733.2007.00173.x. PMID: 17645677.
  36. Brook RA, Kleinman NL, Su J, Corey-Lisle PK, Iloeje UH. Absenteeism and productivity among employees being treated for hepatitis C. Am J Manag Care. 2011 Oct;17(10):657-64. PMID: 22106459.
  37. Su J, Brook RA, Kleinman NL, Corey-Lisle P. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology. 2010 Aug;52(2):436-42. doi: 10.1002/hep.23726. PMID: 20683943.
  38. Brook RA, Rajagopalan K, Kleinman NL, Melkonian AK. Absenteeism and health-benefit costs among employees with MS. Curr Med Res Opin. 2009 Jun;25(6):1469-76. doi: 10.1185/03007990902905468. PMID: 19422277.
  39. Hersh CM, Brook RA, Beren IA, et al. The implications of suboptimal year-1 outcomes with disease-modifying therapy in employees with multiple sclerosis. J Med Econ. 2021 Jan-Dec;24(1):479-486. doi: 10.1080/13696998.2021.1906013. PMID: 33739915.
  40. Brook RA, Kleinman NL, Rajagopalan K. Employee costs before and after treatment initiation for bipolar disorder. Am J Manag Care. 2007 Apr;13(4):179-86. PMID: 17408337.
  41. Brook RA, Wahlqvist P, Kleinman NL, Wallander MA, Campbell SM, Smeeding JE. Cost of gastro-oesophageal reflux disease to the employer: a perspective from the United States. Aliment Pharmacol Ther. 2007 Sep 15;26(6):889-98. doi: 10.1111/j.1365-2036.2007.03428.x. PMID: 17767473.
  42. Brook RA, Kleinman NL. Human Capital Costs and Absenteeism among Employees with Various Conditions. In: Rizzo MF, Gallo A, eds. Human Capital and Resources: Developments, Management and Strategies. Hauppauge, NY: Nova Science Publishers, Inc. 2012:33-60. ISBN: 978-1-61470-898-8.
  43. Lynch WD, Markosyan K, Melkonian AK, Pesa J, Kleinman NL. Effect of antihypertensive medication adherence among employees with hypertension. Am J Manag Care. 2009 Dec;15(12):871-80. PMID: 20001168.
  44. Elixhauser A, Steiner C, Harris DR, Coffey RM. Comorbidity measures for use with administrative data. Med Care. 1998 Jan;36(1):8-27. doi: 10.1097/00005650-199801000-00004. PMID: 9431328.
  45. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-83. doi: 10.1016/0021-9681(87)90171-8. PMID: 3558716.
  46. Strand V, Jones TV, Li W, Koenig AS, Kotak S. The impact of rheumatoid arthritis on work and predictors of overall work impairment from three therapeutic scenarios. Int J Clin Rheumatol. 2015.
  47. Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M. Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis. J Manag Care Spec Pharm. 2018 Apr;24(4):344-352. doi: 10.18553/jmcp.2018.24.4.344. PMID: 29578852.
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership